LDS/Medical Tests/Ecstasy, Urine

Ecstasy, Urine

Ecstasy drugs represent a group of drugs similar to analogues of amphetamine including 3, 4-methylenedioxyamphetamine (MDA), 3, 4 methylenedioxymethamphetamine (MDMA) and 3, 4–methylenedioxyethylamphetamine (MDEA). This group of drugs are central nervous system (CNS) stimulants popularly abused for their psychotropic effects. At low doses, both MDMA and MDA produce euphoria, increased self-awareness, and an increased sense of trust. At higher doses, they are thought to be hallucinogenic. Toxic effects are similar to those of other CNS stimulants and include anxiety, depression, tachycardia, elevated blood pressure, cardiac arrhythmias, pupil dilation, and sleep disorders.

The drug is metabolized at different rates in different individuals due to genetic variations in the cytochrome p450 (CYP450) metabolizing enzyme. Toxicity or death has been reported in individuals who concurrently consumed certain monoamine oxidase inhibitors such as phenelzine, tranylcypromine and moclobemide. Death has been reported in individuals who concurrently consumed ritonavir, an inhibitor of cytochrome p450 enzymes.

The Ecstasy assay is used for qualitative and/or semi-quantitative detection of Ecstasy drugs in human urine. Ecstasy is usually tested in conjunction with other drug screen tests as drug screen panel.

  • Drug abuse evaluation
  • Toxicity assessment
A positive result indicates only the presence of these drugs and does not necessarily correlate with the extent of physiological and psychological effects. Drug screen tests are susceptible to false positives so that any positive screen result should be confirmed by a non-immunologic method such as GC, TLC, or GC/MS.

Negative (less than cutoff)

 

Cut-Off Ranges: Cut-Off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular manufacturer of the assay.

 

 

Enzyme Immunoassay

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
Any Positive test result should be confirmed by either GC, TLC, or GC/MS. Additional supportive testing may include Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC, Urine Drug Screen.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Urine Testing for Drug of Abuse. National Institute on Drug Abuse (NIDA), Research Monograph. 73 (1986)
  • Mandatory Guidelines for Federal Workplace Drug Testing Programs. National Institute on Drug Abuse. Federal Register Vol. 53, No 69, pp11970 (1988).
  • Emerg Med J. 2011 Jun;28(6):462-6. [PMID: 21602168]